Significant Ownership of Versant Venture Capital VI, L.P.

Signature - Title
/s/Max Eisenberg - Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the GP of Versant Ventures VI GP, L.P., the GP of Versant Venture Capital VI, L.P.
Location
San Francisco, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Versant Venture Capital VI, L.P..

Notify me when Versant Venture Capital VI, L.P. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Versant Venture Capital VI, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TPST Tempest Therapeutics, Inc. Common Stock, par value $0.001 per share 3.7% $1,108,210 -$13,298,570 162,972 -92% Versant Vantage II, L.P. 11 Aug 2025
LENZ LENZ Therapeutics, Inc. Common Stock, par value $0.00001 per share 3.4% $48,936,901 -$6,192,532 1,050,599 -11% Versant Venture Capital VI, L.P. 05 Nov 2025
GLUE Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share 3.4% $35,080,976 -$17,220,640 2,236,708 -33% Versant Venture Capital VI, L.P. 07 Jan 2026
LVTX LAVA Therapeutics N.V. Common Shares, par value Euro 0.12 per share 0% $0 -$3,626,915 0 -100% Versant Venture Capital VI, L.P. 19 Sep 2025

Schedules 13D/G Reported by Versant Venture Capital VI, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.